AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04890704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcuminoid
Description: Patients were stratified according to baseline eGFR and diabetes status with 1:1 assignment into curcuminoids and placebo group. Curcuminoids (250 mg capsules) were purchased from the Government Pharmaceutical Organization of Thailand (Anti-ox® registration number 1A 1/60(H)), which contained curcumin: demethoxycurcumin: bis-demothoxycurcumin at the ratio of 1:0.5:0.2.
Study NCT04890704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules were used for the placebo from the same manufacturer.
Study NCT00084617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00084617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00084617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT02720224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: 15 mg \[14C\]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
Study NCT03178422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CQSS2
Description: Nicotine Replacement Therapy
Study NCT03178422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicoDerm CQ Patch
Description: Nicotine Replacement Therapy
Study NCT01230385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
Study NCT01230385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
Study NCT01230385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
Study NCT01230385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
Study NCT01230385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lersivirine
Description: Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
Study NCT01770782 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgically Assisted Rapid Maxillary Expansion (SARME)
Description: Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
Study NCT02395250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-GPC3 CAR T
Study NCT03432637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spontaneous ventilation
Description: thoracoscopic lobectomy under spontaneous ventilation
Study NCT03432637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intubated anesthesia with single-lung mechanical ventilation
Description: undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation
Study NCT00496717 — intervention group
Intervention type: DEVICE
Intervention: Helicoidal fast scann
Description: Each patient will have an computed aortic tomodensitometric scan without contrast injection. This procedure lasts few minutes and irradiation is low. The aortic calcium scoring is calculated using a specific program included in the scan machine
Study NCT00502242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramipril
Description: Capsule - initial treatment is 5 mg (active)- oral - once per day
Study NCT00502242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ramipril
Description: Capsule - initial treatment is 5 mg (placebo) - oral - once per day
Study NCT03817853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
Study NCT03817853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
Study NCT03817853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
Study NCT03817853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
Study NCT03817853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone/Methylprednisolone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
Study NCT03817853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
Study NCT05310682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data informed Platfrom for health
Description: The DIPH promotes local data use for decision-making, priority-setting, planning and course correction at the district level by introducing a structured and collaborative process within the administration cadre. The DIPH is delivered as a package of job aids and guidelines. It involves grouping stakeholders who are brought together to deliberate on issues in a virtual platform facilitated by regular meetings. The package facilitates stakeholders' meetings in five steps: Assessment, Engagement, Definition, Planning and Follow-up. Together, these steps make up one whole cycle of the DIPH completed over four months. Each cycle looks at a specific health theme, identified in the early stages of the cycle itself. The package also includes a digital interface where everyone can regularly review data and check on progress. Note: LSHTM has exempted this study from having a sponsor, as DIPH is implemented at the health system administration level.
Study NCT02685176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)
Description: A heater (STK Heatpac) will be used in the active warming arms of the study.
Study NCT01770782 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laser Scanner
Description: Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
Study NCT02151396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Study NCT02151396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Study NCT01278199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medicals measures
Description: Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 > 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.~If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.~The administration of antibiotherapy by general mode according to the clinician appreciation.~The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation.
Study NCT01278199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bronchial artery embolization
Description: The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
Study NCT02178449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Study NCT02178449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02178449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02178449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02416791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.
Study NCT02416791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy will be administered for 40 minutes.
Study NCT02766400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Training
Study NCT02416791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be administered for 40 minutes.
Study NCT02766400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Directed Training
Study NCT02416791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational therapy will be administered for 40 minutes.
Study NCT01159496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377 (SAM-760)
Description: Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
Study NCT04117256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Current Stimulation
Description: 20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm
Study NCT04117256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham DCS
Description: 20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
Study NCT03148301 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey
Study NCT05736458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
Study NCT01159496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule, once daily for 14 days
Study NCT02721238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% Albumin
Study NCT00566215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal exclusion plus omentectomy
Description: Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed.
Study NCT00566215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal exclusion without omentectomy
Description: Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
Study NCT02721238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte
Study NCT04242927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid +Routine care
Description: Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
Study NCT04242927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routinely apply urea ointment and provide best supportive care.
Study NCT01826591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Counseling/instruction on how to follow a low-carbohydrate diet.
Study NCT01826591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet
Description: Counseling/instruction on how to follow a low-fat diet.
Study NCT01826591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App
Description: Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
Study NCT01893151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
Study NCT01893151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iguratimod placebo
Description: Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week.
Study NCT00692172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: intramuscular injection (IM)
Study NCT02359526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IlUVIEN
Description: All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
Study NCT02869217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02869217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1301
Study NCT02869217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02955992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving communication during the end-of-life process
Study NCT02006407 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Cranial Radiotherapy
Description: Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
Study NCT02006407 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI with Diffusion Tensor Imaging (DTI)
Description: Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
Study NCT02006407 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuro-cognitive Testing (CogState)
Description: CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
Study NCT02903316 — intervention group
Intervention type: PROCEDURE
Intervention: Fluids
Study NCT03191019 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile-phone app for smoking cessation
Description: Android App for smoking cessation
Study NCT03191019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-phone app for smoking cessation
Description: Android App for smoking cessation
Study NCT05736458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
Study NCT05736458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High controllability TMS target
Description: Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
Study NCT00355771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
Study NCT00355771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet OD in the morning for 8 weeks
Study NCT03663699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: free access to the exergaming platform PlayPulse for 24 weeks
Study NCT02411721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Intervention
Description: 1. Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.~2. The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.~3. Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination.
Study NCT01914848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Care Planning ACP
Description: Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
Study NCT01914848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: A routine care discharge planning with the social service
Study NCT04703881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES ActaGain
Description: AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.
Study NCT00618657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00618657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT00618657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00727298 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
Study NCT00618657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00618657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Optional correlative studies
Study NCT00618657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
Study NCT02665000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Structured training programme
Description: Participants will undergo 5-days training sessions
Study NCT03907501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: an herbal prebiotic plus probiotic
Study NCT02685176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No heat
Description: No active heating provided post cooling
Study NCT03907501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Triphala alone
Study NCT00508235 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about the patient's relationship with their best friend.
Study NCT01253876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy milk, Caw's milk
Study NCT03907501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert capsule
Study NCT03326999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obturator nerve regional block
Description: Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
Study NCT03326999 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Adductor canal regional block
Description: Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
Study NCT03326999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor canal regional block
Description: Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.